Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.
Five years later, what are the wider impacts of the US Supreme Court's Myriad decision on subject-matter eligibility and patent prosecution for nature-based products beyond isolated DNA?
Incorporating career development into PhD course offerings can help biomedical students better understand themselves, as well as the job market, and to adopt a 'can-do' attitude in developing their own paths.
